Ketosis-Prone Type 2 Diabetes in Patients of Sub-Saharan African Origin

Clinical Pathophysiology and Natural History of β-Cell Dysfunction and Insulin Resistance

  1. Franck Mauvais-Jarvis1,
  2. Eugène Sobngwi1,
  3. Raphaël Porcher2,
  4. Jean-Pierre Riveline3,
  5. Jean-Philippe Kevorkian4,
  6. Christian Vaisse5,
  7. Guillaume Charpentier3,
  8. Pierre-Jean Guillausseau4,
  9. Patrick Vexiau1 and
  10. Jean-François Gautier1
  1. 1Department of Endocrinology & Diabetes, Saint-Louis Hospital and University of Paris VII School of Medicine, Paris, France
  2. 2Department of Medical Biostatistics, Saint-Louis Hospital and University of Paris VII School of Medicine, Paris, France
  3. 3Department of Diabetes and Metabolic Diseases, Sud Francilien Hospital, Corbeil-Essonnes, France
  4. 4Department of Internal Medicine B, Lariboisiere Hospital, Paris, France
  5. 5Diabetes Research Center, Department of Medicine, University of California San Francisco, San Francisco, California
  1. Address correspondence and reprint requests to Franck Mauvais-Jarvis, MD, Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Baylor College of Medicine, One Baylor Plaza, 520B Houston, TX 77030. E-mail: fmjarvis{at}bcm.tmc.edu

Abstract

Nonautoimmune ketosis-prone diabetic syndromes are increasingly frequent in nonwhite populations. We have characterized a cohort of patients of sub-Saharan African origin who had ketosis-prone type 2 diabetes (n = 111), type 1 diabetes (n = 21), and type 2 diabetes (n = 88) and were admitted to a hospital for management of uncontrolled diabetes. We compared epidemiological, clinical, and metabolic features at diabetes onset and measured insulin secretion (glucagon-stimulated C-peptide) and insulin action (short intravenous insulin tolerance test) during a 10-year follow-up. Ketosis-prone type 2 diabetes shows a strong male predominance, stronger family history, higher age and BMI, and more severe metabolic decompensation than type 1 diabetes. In ketosis-prone type 2 diabetes, discontinuation of insulin therapy with development of remission of insulin dependence is achieved in 76% of patients (non–insulin dependent), whereas only 24% of patients remain insulin dependent. During evolution, ketosis-prone type 2 diabetes exhibit specific β-cell dysfunction features that distinguish it from type 1 and type 2 diabetes. The clinical course of non–insulin-dependent ketosis-prone type 2 diabetes is characterized by ketotic relapses followed or not by a new remission. Progressive hyperglycemia precedes and is a strong risk factor for ketotic relapses (hazard ratio 38). The probability for non–insulin-dependent ketosis-prone type 2 diabetes to relapse is 90% within 10 years, of whom ∼50% will become definitively insulin dependent. Insulin sensitivity is decreased in equal proportion in both ketosis-prone type 2 diabetes and type 2 diabetes, but improves significantly in non–insulin-dependent ketosis-prone type 2 diabetes, only after correction of hyperglycemia. In conclusion, ketosis-prone type 2 diabetes can be distinguished from type 1 diabetes and classical type 2 diabetes by specific features of clinical pathophysiology and also by the natural history of β-cell dysfunction and insulin resistance reflecting a propensity to glucose toxicity.

Footnotes

    • Accepted December 1, 2003.
    • Received June 8, 2003.
« Previous | Next Article »Table of Contents